Published in:
Open Access
01-06-2019 | Anaphylaxis | Immunotherapy and Immunomodulators (B Vickery, Section Editor)
GRADE-ing the Benefit/Risk Equation in Food Immunotherapy
Authors:
Bettina Duca, Nandinee Patel, Paul J. Turner
Published in:
Current Allergy and Asthma Reports
|
Issue 6/2019
Login to get access
Abstract
Purpose of Review
We reviewed the existing evidence base to desensitisation for food allergy, applying the Grading of Recommendations, Assessment, Development and Evaluation approach to discuss whether desensitisation is likely to become part of routine treatment for patients with food allergy.
Recent Findings
Desensitisation for food allergy to peanut, egg and cow’s milk is efficacious, but whether such interventions are cost-effective is less clear, due to the issues over a sustained desensitisation effect and the increase in allergic reactions occurring in patients on treatment. Few studies have assessed the change in health-related quality of life associated with treatment, and most have not considered discordance between parent-reported changes in health-related quality of life (HRQL) outcomes compared to those of the patients themselves; none to date have controlled for the improvement in HRQL occurring after initial challenge which will confound outcomes.
Summary
The lack of longer-term safety and cost-effectiveness data, as well as an absence of current consensus in the reporting of patient-relevant outcomes, must be addressed in order to be able to recommend the introduction of desensitisation as a routine treatment in healthcare systems.